Production & Sales

Janssen Pharmaceutical to supply up to 400 million Covid-19 vaccine doses to EU

European Commission (EC) has approved an advance purchase agreement under which Janssen Pharmaceutical Companies will supply up to 400 million doses of its Covid-19 vaccine candidate.

J&J, GRAM collaborate on manufacturing of Covid-19 vaccine candidate

Johnson & Johnson (J&J) company Janssen Pharmaceuticals has partnered with injectable contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing (GRAM) to produce its SARS-CoV-2 vaccine candidate.

Sanofi, GSK sign agreements with Government of Canada to supply 72 million doses of adjuvanted Covid-19 vaccine

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted Covid-19 vaccine, beginning in 2021.

Vifor Pharma Group announces successful sale of OM Pharma

Vifor Pharma has announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding.

Sanofi, GSK sign deal to supply 300 million doses of Covid-19 vaccine in EU states

British drugmaker GlaxoSmithKline (GSK) and French pharmaceutical firm Sanofi have entered into an advanced purchase agreement with the European Commission (EC) to supply up to 300 million doses of adjuvanted Covid-19 vaccine.

Santen and US ophthalmic company Eyevance enter into share purchase agreement

Santen Pharmaceutical and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc. ("Eyevance").

Dr. Reddy’s, RDIF partner to supply 100 million doses of Sputnik V vaccine in India

Dr. Reddy's Laboratories has agreed to collaborate with the Russian Direct Investment Fund (RDIF) to conduct clinical trials and supply Sputnik V vaccine for Covid-19 in India.

Pfizer, BioNTech to supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2

Pfizer and BioNTech announced that they had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for further 100 million doses.

Takeda divests select non-core assets in Europe to Cheplapharm for approximately $562m

Takeda Pharmaceutical announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm.